[242] The method of treatment according to [239], wherein the PARP inhibitor is niraparib or a pharmacologically acceptable salt thereof.

[243] The method of treatment according to [239], wherein the PARP inhibitor is talazoparib or a pharmacologically acceptable salt thereof.

[244] The method of treatment according to [239], wherein the PARP inhibitor is veliparib or a pharmacologically acceptable salt thereof.

[245] The method of treatment according to any one of [211] to [244], wherein the antibody-drug conjugate and the PARP inhibitor are separately contained as active components in different formulations, and are administered simultaneously or at different times.

[0075]

[246] The method of treatment according to any one of [211] to [245], wherein the method of treatment is for treating at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head-and-neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, bladder cancer, prostate cancer, uterine carcinosarcoma, gastrointestinal stromal tumor, kidney cancer, and sarcoma.

Results of a combination of TROP2-ADC (1) and rucaparib are shown in Figure 31. Single administration of rucaparib showed TGI of 9% and single administration of TROP2-ADC (1) showed TGI of 82%. On the other hand, combined administration of TROP2-ADC (1) and rucaparib showed TGI of 97% and exhibited a significantly superior tumor growth suppression effect than single administration of rucaparib ($P < 0.0001$) and had a higher tumor growth inhibition than single administration of TROP2-ADC (1).

[0309]

Results of a combination of TROP2-ADC (1) and talazoparib are shown in Figure 32. Single administration of talazoparib showed TGI of 27% and single administration of TROP2-ADC (1) showed TGI of 82%. On the other hand, combined administration of TROP2-ADC (1) and talazoparib showed TGI of 98% and exhibited a significantly superior tumor growth suppression effect than single administration of talazoparib ($P < 0.0001$) and had a significantly superior tumor growth suppression effect ($P = 0.0209$) than single administration of TROP2-ADC (1).

[0310]

Example 19: Antitumor study (9)

Mouse: Female 5-6-week-old BALB/c nude mice (CHARLES RIVER LABORATORIES JAPAN, INC.) were subjected to the experiments.